Midostaurin

Midostaurin

Cat. No.: PI120685112

Description: Midostaurin is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutationpositive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.

Midostaurin
Product Details
CAS 120685-11-2
Trade Names Rydapt
Synonyms N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-4-yl]-N-methylbenzamide
Molecular Formula C35H30N4O4
Molecular Weight 570.649
Available Formulations Oral Solid
Technology Fermentation
Available DMF/CEP/GMP US DMF

* Our products are for research use only.

Get in Touch

We’re glad to help you with your products and services demands. For any inquiry, question or recommendation, please send an email to or fill out the following form.

Verification code
For product and service inquiries icon1

For product and service inquiries, please use our online system or send an email to .

For product and service inquiries icon2